{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.05","value":"73.7"},{"groupId":"OG001","spread":"18.13","value":"72.5"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.81","value":"-0.6"},{"groupId":"OG001","spread":"16.34","value":"-5.9"}]}],"title":"Change at Cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"242"},{"groupId":"OG001","value":"247"}],"units":"Participants"}],"description":"Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"MEAN","populationDescription":"The ITT analysis set included all randomized participants; \"Overall number of participants analyzed\" refers to number of participants evaluable for this outcome measure and \"Number analyzed\" refers to participants evaluable at the specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline to Cycle 6 (21 days per cycle)","title":"HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Questionnaire (EQ-5D-5L) in the ITT Analysis Set","type":"SECONDARY","unitOfMeasure":"Score on a scale"}